← Back to headlines
Ascletis Doses First Patient in Phase III Trial for Oral Weight-Loss Drug
Biotech company Ascletis has administered the first dose to a participant in its global Phase III clinical trial for ASC30, an experimental oral medication designed for chronic weight management. The milestone advances development of a once-daily GLP-1 receptor agonist alternative to injectable treatments.
30 Aug, 10:15 — 30 Aug, 11:02
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (24/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
morningstartaiwan-news
Right
Far R
Geographic diversity— 2 regions9/34
US1Taiwan1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
morningstar12h ago
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - Morningstar
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management Morningstar
Read full article →taiwan-newsMostly Factual13h ago
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - Taiwan News
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management Taiwan News
Read full article →Coverage Timeline
First report: taiwan-news · 30 Aug, 10:15|Full coverage: 2 · 47m|Window: 47m
Left-leaningCenterRight-leaning
